Stockscreener 앱 받기
60.26
1.78%
-1.09
시간 외 거래:
59.80
-0.46
-0.76%
전일 마감가:
$61.35
열려 있는:
$61.5
하루 거래량:
1.79M
Relative Volume:
0.92
시가총액:
$11.66B
수익:
$3.29B
순이익/손실:
$268.74M
주가수익비율:
43.97
EPS:
1.3704
순현금흐름:
$759.12M
1주 성능:
-5.76%
1개월 성능:
-8.86%
6개월 성능:
+8.40%
1년 성능:
+14.52%
1일 변동 폭
$60.17
$61.50
1주일 범위
$60.17
$64.96
52주 변동 폭
$49.26
$70.98
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.26 | 11.66B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 재개 | Morgan Stanley | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board - simplywall.st
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq - AD HOC NEWS
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - sg.finance.yahoo.com
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish - AD HOC NEWS
BioMarin Pharmaceutical Inc. (BM8.F) stock price, news, quote and history - Yahoo Finance UK
BioMarin Pharmaceutical stock holds near its 52-week low - AD HOC NEWS
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews
The Best Healthcare Stocks to Buy - Morningstar
BioMarin Pharmaceutical stock holds near a $12.38 billion value - AD HOC NEWS
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4.05% While Shares Slip 1.75%Earnings Outlook Update - careplusvn.com
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - finance.yahoo.com
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance
BioMarin options flow shows large bullish call spread targeting $100 by April 2027 - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BioMarin Stops Voxzogo Development for Noonan Syndrome - The Globe and Mail
BMO cuts BioMarin stock price target to $97 on Voxzogo focus shift - Investing.com Nigeria
BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) - kalkinemedia.com
BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts - Fierce Pharma
BioMarin Announces Discontinuation of VOXZOGO Development for Pediatric Noonan Syndrome - kalkinemedia.com
BioMarin to discontinue development of Voxzogo for Noonan syndrome in children - Investing.com
BMRN Looks 21.8% Undervalued on GF Value™ Amid Pipeline Shift - GuruFocus
BioMarin shelves Voxzogo in Noonan syndrome (BMRN:NASDAQ) - Seeking Alpha
Form 8K Biomarin Pharmaceutical Inc For: 15 September By Investing.com - Investing.com Canada
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan
BioMarin Pharmaceutical Inc. Announces Appointment of Robert Plenge to Its Board of Directors and Science and Technology Committee, Effective September 10, 2026 - marketscreener.com
BioMarin Pharmaceutical appoints Robert Plenge to board of directors By Investing.com - Investing.com Nigeria
BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board - citybiz
Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com - Investing.com Nigeria
BioMarin appoints Bristol Myers Squibb executive to board - Investing.com
BioMarin appoints Robert Plenge to its Board and Science & Technology Committee - TradingView
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - prnewswire.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals - ChartMill
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com South Africa
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com
BioMarin at Wells Fargo conference: growth, pipeline and integration - Investing.com India
BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com Canada
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView
BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts - Fierce Pharma
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):